Sanofi SA (SNY)’s New Diabetes Play Moves Forward

Sanofi SA (ADR) (NYSE:SNY) starts the week with a new European Union approval for the type 2 diabetes injectable Lyxumia. The drug belongs to a class of GLP-1 agonists currently dominated by Novo Nordisk A/S (ADR) (NYSE:NVO) and Bristol Myers Squibb Co. (NYSE:BMY). Lyxumia probably won’t jump to the front of that class, but could the new drug bolster Sanofi’s blockbuster insulin as it heads toward patent expiration?

Well-established class
The continually growing market of diabetes treatments inspires a wide range of development tactics. GLP-1 agonists stimulate insulin production without causing hyperglycemia — a common side effect of diabetes treatments. Lyxumia comes to market behind a trio of best-selling drugs that kept growing last year.

Sanofi SA (ADR) (NYSE:SNY)Novo Nordisk leads the field with Victoza, which had 2011 revenues of 6 billion Danish krona (about $952 million at current exchange rates) and a 50% sales growth last year. Amylin developed the once-daily Bydureon and once-weekly Byetta injections, which inspired Bristol-Myers Squibb to buy the company last summer. Bristol recently reported its fiscal year and showed Bydureon’s worldwide net sales  at $78 million and Byetta at $149 million.

Lyxumia would need to beat the existing drugs in either dosage convenience or efficacy if it wanted to knock Victoza from its lead position. But Lyxumia suffered criticism that it’s an efficacy clone of Bydureon. Lyxumia had lackluster results in trials when given on its own. But the drug performed better when paired with insulin.

And that’s the real value of Lyxumia for Sanofi. The company’s $5 billion insulin, Lantus, faces patent expiration in 2015. Placing Lantus into a new combo treatment would help alleviate that financial cliff.

The finances
Lyxumia was licensed from Zealand Pharma, and the contract has Sanofi paying the development and commercialization costs of Lyxumia and any relating combination drugs. Zealand receives milestone payments of $275 million plus global net sales royalties.

Foolish bottom line
Sanofi expects to file for U.S. approval for Lyxumia in the first half of this year. The company’s portfolio is large enough that one new drug won’t become a “make or break” issue. But Lyxumia stands out more than most, thanks to help it can provide Lantus.

The article Sanofi’s New Diabetes Play Moves Forward originally appeared on Fool.com and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!